Ser145

Site Information
sDsDyDLsPKAMSRN SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 468390

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 3 , 6 ) , non-small cell lung cancer ( 6 ) , non-small cell lung adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 12 ) , 293 (epithelial) ( 7 , 8 ) , A549 (pulmonary) ( 4 ) , breast ( 1 ) , Calu 6 (pulmonary) ( 6 ) , H2009 (pulmonary) ( 6 ) , H2077 (pulmonary) ( 6 ) , H2887 (pulmonary) ( 6 ) , H322M (pulmonary) ( 6 ) , HCC1359 (pulmonary) ( 6 ) , HCC2279 (pulmonary) ( 6 ) , HCC366 (pulmonary) ( 6 ) , HCC4006 (pulmonary) ( 6 ) , HCC78 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 6 ) , HeLa (cervical) ( 5 , 9 , 10 , 11 , 13 ) , HOP62 (pulmonary) ( 6 ) , LCLC-103H (pulmonary) ( 6 ) , LOU-NH91 (squamous) ( 6 ) , lung ( 3 ) , NCI-H1395 (pulmonary) ( 6 ) , NCI-H1568 (pulmonary) ( 6 ) , NCI-H157 (pulmonary) ( 6 ) , NCI-H1648 (pulmonary) ( 6 ) , NCI-H1666 (pulmonary) ( 6 ) , NCI-H2030 (pulmonary) ( 6 ) , NCI-H2172 (pulmonary) ( 6 ) , NCI-H322 (pulmonary) ( 6 ) , NCI-H460 (pulmonary) ( 6 , 14 ) , NCI-H520 (squamous) ( 6 ) , NCI-H647 (pulmonary) ( 6 ) , PC9 (pulmonary) ( 6 )

Upstream Regulation
Treatments:	MLN8054 ( 11 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
4	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
5	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
6	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
7	Mulhern D (2011) CST Curation Set: 12829; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
8	Mulhern D (2011) CST Curation Set: 12830; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
9	Zhou J (2011) CST Curation Set: 11707; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
10	Zhou J (2011) CST Curation Set: 11708; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
11	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
12	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
13	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
14	Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74 19415658 Curated Info